linjc16/ctgov huggingface dataset:
Video Head Impulse Test and Seasickness Susceptibility

Study Overview
=================
Brief Summary
-----------------
This a case control study on seasickness susceptibility. 86 healthy maritime personal were divided to seasickness susceptible and non susceptible groups based on a seasickness questionnaire (Golding) and motion sickness score. All subjects from both groups underwent video head impulse testing (vHIT). VHIT parameters - gain, asymmetry ect were compared between both groups.

Official Title
-----------------
Video Head Impulse Test and Seasickness Susceptibility

Conditions
-----------------
Sea Sickness

Intervention / Treatment
-----------------
* Diagnostic Test: Video-head impulse testing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18-40 healthy military naval subjects At least six month of active sailing. Exclusion Criteria: A history of hearing loss Ear pathology observed at otoscopic examination A neck injury precluding head movement. Abnormal otoneurological examination findings Subject's withdrawal of informed consent. Failure to complete the video head impulse test.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: seasickness susceptible<br>43 seasickness susceptible maritime crewmembers underwent video-head impulse test | Diagnostic Test: Video-head impulse testing<br>* Video-head impulse testing is a recent diagnostic bed-side test for evaluation of semi-circular canal function.<br>|
| Other: seasickness non-susceptible<br>43 seasickness non-susceptible maritime crewmembers underwent video-head impulse test | Diagnostic Test: Video-head impulse testing<br>* Video-head impulse testing is a recent diagnostic bed-side test for evaluation of semi-circular canal function.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| vHIT gain | measurement of semicircular canal function | Immediate | 
| paired semi-circular canal asymmetry | (|1st canal gain-2nd canal gain|)/(1st canal gain+2nd canal gain) | Immediate | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| anterior semicircular canal gain o ipsilateral horizontal canal gain | anterior semicircular canal gain o ipsilateral horizontal canal gain | Immediate | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
motion sickness, video head impulse test, vestibular testing, seasickness susceptibility
Effect of Heliox on RSV Bronchiolitis

Study Overview
=================
Brief Summary
-----------------
Helium is an inert gas with a density almost one-seventh of that of air. Based on its properties breathing a mixture of helium and oxygen (heliox) will lead to a reduction in resistance through narrowed airways and consequently decreases the work of breathing. Participating infants with RSV acute bronchiolitis will be supplied with heliox (ration of 21 oxygen and 79 helium) delivered through a flow nasal cannula to evaluate heliox effect in improving their oxygenation. Heliox will act as an additive therapy to improve oxygenation in patients with lower respiratory tract infection caused by respiratory Syncytial Virus (RSV) and will decrease the need for more complicated therapies.

Official Title
-----------------
Effect of Heliox on Infants With Respiratory Syncytial Virus Acute Bronchiolitis-A Revisit Study

Conditions
-----------------
RSV Infection, Acute Bronchiolitis

Intervention / Treatment
-----------------
* Drug: Heliox
* Drug: Air


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age fro 1 month till 2 years RSV acute bronchiolitis without any supplemental oxygen. Exclusion Criteria: oxygen supplement or mechanical ventilation requirement congenital anomalies of the heart chronic lung disease including bronchopulmonary dysplasia Failure to obtain an informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 2 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Heliox group<br>receive Helium oxygen mixture 21:79 via nasal cannula 2L/min | Drug: Heliox<br>* Heliox (21:79) via nasal cannula 2 litter per minutes<br>|
| Active Comparator: Air group<br>receive oxygen 21%via nasal cannula 2L/min | Drug: Air<br>* Air 21% via nasal cannula 2 litter per minutes<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement in oxygenation | Arterial blood samples will be withdrawn through an arterial stab to determine partial pressure of arterial oxygen (PaO2) | change from baseline at 24 hours after treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| improvement of respiratory distress | measured by the Modified Wood's Clinical Asthma Score | change from baseline at 24 hours after treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Heliox
Quantificational Enhancement Pattern Analysis Using a Novel Software Vuebox of Contrast-enhanced Harmonic Endoscopic Ultrasonography for Differential Diagnosis Between Adenomas and Cholesterol Polyps

Study Overview
=================
Brief Summary
-----------------
The investigators' study is a prospective study to evaluate the enhancement pattern of contrast-enhanced endoscopic ultrasonography and suggest the criterions for differential diagnosis between gallbladder polyps by using software program of quantitative analysis.

Conditions
-----------------
Gallbladder Polyp

Intervention / Treatment
-----------------
* Device: Quantitative analysis by using the new developed software program VueBox


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patient who will be received the exams to evaluate the polyps for treatment plan of surgical treatment have a plan to evaluate by EUS 19 years of age or older Exclusion Criteria: difficult undergo EUS, allergy for contrast agent, renal failure, acute coronary syndrome pulmonary hypertension, 6) pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Contrast enhanced EUS group<br>Contrast enhanced EUS with quantitative analysis | Device: Quantitative analysis by using the new developed software program VueBox<br>* After acquiring the EUS image by a regular procedure of EUS and contrast-enhanced with one of the fluoro-gas-containing contrast agents (SonoVue, Bracco, Germany), whole video is recorded on the embedded HDD (hard disk drive) of the US system for later analysis. The videos will be analyzed by using the VueBox software (Bracco Suisse SA, Geneva, Switzerland). After surgical treatment, we will compare the results of quantitative analysis with surgical pathology.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Accuracy between visual assessment and quantificational analysis based on surgical pathology |  | 1day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sensitivity between visual assessment and quantificational analysis based on surgical pathology |  | 1 day | 
| Specificity between visual assessment and quantificational analysis based on surgical pathology |  | 1 day | 
| PPV between visual assessment and quantificational analysis based on surgical pathology |  | 1 day | 
| NPV between visual assessment and quantificational analysis based on surgical pathology |  | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Quantitative analysis, contrast enhanced endoscopic ultrasonography
Phase 2 Study of Gemcitabine and Docetaxel Combination Chemotherapy in Patients With Carcinoma of Unknown Primary

Study Overview
=================
Brief Summary
-----------------
It's a phase 2, single arm study of gemcitabine an docetaxel combination in patients with carcinoma of unknown primary.

Official Title
-----------------
Phase 2 Study of Gemcitabine and Docetaxel Combination Chemotherapy in Patients With Carcinoma of Unknown Primary

Conditions
-----------------
Carcinoma of Unknown Primary

Intervention / Treatment
-----------------
* Drug: gemcitabine/docetaxel combination


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. age>=20 2. pathologically confirmed patients with carcinoma of unknown primary 3. unfavorable type of CUP 4. ECOG PS 0-2 5. more than 1 evaluable lesion 6. life expectancy > 12 weeks 7. no prior history of chemotherapy 8. more than 2 weeks after surgery or radiotherapy 9. proper organ function 10. written informed consent Exclusion Criteria: 1. favorable group CUP squamous cell carcinoma in the cervical or inguinal LN only women with axillary LN metastasis only women with peritoneal carcinomatosis only well-differentiated neuroendocrine tumors poorly-differentiated tumors with midline tumor or elevated human HCG/AFP men with adenocarcinoma and elevated PSA 2. severe, unstable heart disease 3. uncontrolled systemic disease (DM, HTN, hypothyroidism, infection...) 4. pregnant or feeding women 5. current CNS tumor (except total removal or WBRT/GKS done)

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intervention arm<br>D1, 8 Gemcitabine 1000mg/m2 IV over 30 minutes D1, 8 Docetaxel 35mg/m2 IV over 1hr | Drug: gemcitabine/docetaxel combination<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival |  | one year after later patients enrolled |
Comparison of Postoperative Aqueous Flare After 20G Versus 23G Pars Plana Vitrectomy

Study Overview
=================
Brief Summary
-----------------
To compare postoperative inflammation and breakdown of blood-retinal barrier as measured by a laser flare-cell meter in 20G versus 23G vitrectomy.

Official Title
-----------------
Comparison of Postoperative Aqueous Flare After 20G Versus 23G Pars Plana Vitrectomy

Conditions
-----------------
Macular Hole, Macular Pucker

Intervention / Treatment
-----------------
* Procedure: 20G Vitrectomy
* Procedure: 23G vitrectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age > 18 years macular hole macular pucker willing to perform follow up written signed consent Exclusion Criteria: other relevant eye disease: retinal detachment, provect cataract, diabetic retinopathy, AMD, relevant glaucoma, pre-surgery except for cataract surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 20G<br>20G vitrectomy with scleral and conjunctival sutures for closure | Procedure: 20G Vitrectomy<br> <br> |
| Active Comparator: 23G<br>23G transconjunctival sutureless vitrectomy | Procedure: 23G vitrectomy<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Alteration of aqueous flare between preoperative and 3-week-postoperative time point |  | 3 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual acuity change |  | 3 weeks | 
| Closure of Macular hole |  | 3 weeks |
Different Genetic Features Associated With Hepatic Carcinogenesis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to identify different genetic features in hepatocellular carcinoma. It will assist in predicting individual risks of disease progression and would help to clarify pathophysiological mechanisms of HCC.

Detailed Description
-----------------
Hepatocellular carcinoma (HCC) is a leading cause of cancer deaths in Taiwan. HCC normally develops as a consequence of underlying liver disease and is most often associated with cirrhosis. Surgical resection and liver transplantation are current best curative options to treat HCC. However, recurrence or metastasis is quite common in patients who have had a resection and survival rate is 30% to 40% at 5 years postoperatively. MicroRNAs, small non-coding RNA, act as endogenous RNA interference by post-transcription regulation. Recent studies suggest that microRNAs may act as tumor suppressors or oncogenes and altered microRNA expression levels may play an important role in the cancer initiation and progression. Several studies, including ourselves, have shown that specific microRNAs are aberrantly expressed in malignant HCC tissues compared to normal counterpart. Although many microRNA profiling studies were done to diagnose hepatocarcinogenesis, data about prognostic significances for postsurgical survival are very limited. The main point of this study is to develop a predictive signature for postsurgical survival in HCC patients.

Official Title
-----------------
Identification of Survival-related microRNAs in Hepatocellular Carcinoma

Conditions
-----------------
Hepatocellular Carcinoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: clinical diagnosis of hepatocellular carcinoma Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>tumor tissues of HCC patients | |
| 2<br>paired nontumor tissues of HCC patients | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
microRNA
Database of Monochorionic Pregnancies

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to collect and analyze data regarding natural history, indications for fetal interventions, and maternal and fetal/neonatal outcomes associated with complicated monochorionic twin pregnancy.

Official Title
-----------------
Database: Standardized Prenatal Management and Perinatal Outcome of Complicated Monochorionic Pregnancies

Conditions
-----------------
Monochorionic Diamniotic Placenta, Monochorial Monoamniotic Placenta, Twin; Complicating Pregnancy, Twin to Twin Transfusion Syndrome, Twin Reversal Arterial Perfusion Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The study population will consist of MC pregnancies (maternal, fetal, and neonatal data) that have undergone evaluation and/or treatment for complications attributable to monochorionic twin pregnancy at the University of Miami. Maternal age 18 years and older. Exclusion Criteria: Participation declined or consent not granted in prospective arm Loss to follow-up
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Monochorionic Pregnancy Group<br>Participants with complicated monochorionic pregnancies (MC) will be followed prospectively beginning at the time of the mother's evaluation for a complication related to monochorionic (MC) multiple pregnancies through delivery of the child and follow-up of the child to 12 months of life. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with Preterm Delivery | Preterm delivery is defined as birth <37 weeks gestation | Up to 42 weeks gestation | 
| Number of participant with Premature Spontaneous Rupture of the Membranes | As per clinical evaluation | Up to 42 weeks | 
| Number of Infant Deaths | The Number of Infant Deaths | Up to 12 months post infant delivery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
multiple pregnancies, Twins
A Study of Sweat Testing Using a Quantitative Patch

Study Overview
=================
Brief Summary
-----------------
The primary aim of the study is to determine if the CF Quantum Sweat Test provides sweat chloride results that are equivalent to the results from traditional sweat testing. The secondary aim of the study is to assess the quantity not sufficient rate of the CF Quantum Sweat Test compared to traditional sweat testing.

Detailed Description
-----------------
All 50 states and the District of Columbia are performing newborn screening for cystic fibrosis (CF). Infants who have a positive newborn screen require follow-up with a sweat test. Gibson-Cooke Quantitative Pilocarpine Iontophoresis (GCQPIT) requires collecting sweat in microbore tubing or on gauze/filter paper and analyzing sweat using a chloridometer. This test has many difficulties including specimens that are quantity not sufficient (QNS), many steps of pipetting solutions in the laboratory, and the need for a chloridometer to analyze sweat chloride concentration. The only manufacturer of a chloridometer has ceased production of this instrument. The CF Quantum® Sweat Test System (CFQT) overcomes all of the difficulties of GCQPIT. This pilot study will determine if the CFQT provides results that are equivalent to GCQPIT.

Official Title
-----------------
A Study of Sweat Testing Using a Quantitative Patch

Conditions
-----------------
Cystic Fibrosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: clinical diagnosis of cystic fibrosis patients who require a sweat test Exclusion Criteria: Infants less than 48 hours of age Patient is receiving oxygen by open delivery collection site has diffuse inflammation or rash

Ages Eligible for Study
-----------------
Minimum Age: 2 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| cystic fibrosis patients<br>cystic fibrosis patients | |
| non-cystic fibrosis patients<br>non-cystic fibrosis patients | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| sweat chloride value | Sweat chloride measurements obtained by GCQPIT and CFQT | once, at enrollment (baseline) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| QNS rate | QNS rate of CFQT compared to GCQPIT | once, at enrollment (baseline) |
Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the efficacy, safety and patient acceptability of Somatuline Autogel in patients with acromegaly previously treated with octreotide LAR.

Official Title
-----------------
A Phase IV, Open-label, Single Group Study to Evaluate the Dosing, Efficacy and Safety of Lanreotide Autogel® in Patients With Acromegaly Previously Treated With Octreotide LAR

Conditions
-----------------
Acromegaly

Intervention / Treatment
-----------------
* Drug: Lanreotide (Autogel formulation)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of acromegaly The patient must have been tested at Week -4 (4 weeks prior to the Baseline visit) and shown to have a GH level <10 mU/L. The patient must have been treated with a stable dose of octreotide LAR for at least four months prior to study entry Life expectancy of at least 2 years Exclusion Criteria: Adenectomy within past 6 months, or likely during study period Radiotherapy for acromegalic disease within 1 year, or likely during study period Unstable concomitant dopamine agonist therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Lanreotide (Autogel formulation)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The percentage of patients with GH control (<5.0 mU.L) and normalised IGF-1 at week 44 compared to the baseline (Week 0) visit. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The percentage of patients with GH control (< 5.0 mU/L) at each visit to week 44 compared to the baseline (Week 0) visit. |  |  | 
| The percentage of patients with normalised IGF-1 compared to the baseline visit. |  |  | 
| Change in the GH values compared to the baseline (Week 0) visit. |  |  | 
| Change in the IGF-1 values compared to the baseline (Week 0) visit. |  |  | 
| Change in serum lanreotide levels compared to the baseline (Week 0) visit. |  |  | 
| Change in the serum octreotide levels compared to the baseline visit. |  |  | 
| Patient evaluation of lanreotide Autogel treatment compared with evaluation of octreotide LAR treatment. |  |  | 
| Investigator evaluation of lanreotide Autogel treatment compared with evaluation of octreotide LAR treatment. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
acromegaly, growth hormone